CTRI/2023/08/056773尚未招募Unknown
A Multi-center, Open Label, Single Arm, Prospective, Observational Study to Evaluate the Effectiveness and Safety of Whey Protein Isolate (WPI) Based Nutritional Supplement in Coronary Artery Bypass Surgery (CABG) Patients - NI
Otsuka Pharmaceutical India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Patients with age of = 18 to 70 years and with the clinical diagnosis of CAD (coronary artery disease) undergoing CABG surgery.
- •2. Patients/LAR who are willing to provide voluntary written informed consent to participate in the study.
- •3. Patients receiving nutrition as per standard care.
- •4. Expected length of ICU/hospital stay is minimum 5 days.
- •5. Patients who in the opinion of physician are suitable to receive oral WPI based nutritional supplement.
- •6. Patients who will be able to adhere to study visit schedule and other protocol requirements.
- •After the screening and confirmation, the patient will receive Whey Protein Isolate based nutritional supplement 24-48 hrs. after the CABG surgery based on discretion of physician/dietician for 30 days
排除标准
- •1. Patients taking enteral (tube feeding) or parenteral nutritional supplements or any other form of protein supplement.
- •2. Patients having known allergy or contraindication for use of WPI based nutritional supplements.
- •3. Pregnant or breastfeeding women.
- •4.Patients with BMI >30 kg/m2.
- •5. Patient with severe and life-threatening complication(s) or patients who are unlikely to survive the next 48-72 hrs. at the time of enrollment (as per physician’s discretion).
- •6. Patients using other experimental drugs or participating in other clinical trial in the prior one month.
- •7. Any clinical condition that would preclude participation in the study as per investigator’s opinion.
研究者
相似试验
尚未招募
4 期
A clinical study to Evaluate Safety and Efficacy of Vilanterol 40 mcg and Glycopyrronium 63 mcg as maintenance treatment in moderate to severe COPD patients.CTRI/2024/06/069544upin Ltd
招募中
4 期
Phase IV Study to Assess the Safety and Effectiveness of Fixed Dose Combination (Fluticasone Furoate 100 mcg and Glycopyrronium Bromide 50 mcg and Vilanterol Trifenatate 25 mcg) Inhalation powder for maintenance treatment of Patients with Moderate to Severe Chronic Obstructive Pulmonary DiseaseCTRI/2024/06/069178Dr Lokesh Kumar General Manager
尚未招募
Unknown
Study to Evaluate the Effectiveness of Deferiprone Capsules in Patients Recovering from a Recent Heart AttackCTRI/2024/08/072100Synergy Superspecialty Hospital
招募中
不适用
utrition supplement for tube feeding assessed in hospitalized (ICU Stay) patientsCTRI/2022/12/047818Dr Reddys Laboratories
已完成
2 期
A Prospective, Multicenter, Single arm, Open label, Pilot Clinical Study of MeRes 100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of de-novo native Coronary Artery LesionsCTRI/2015/04/005706Meril Life Sciences Pvt Ltd108
